Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Baillie Gifford -International Concentrated Growth Lawrence Burns / Paulina McPadden | “We added three new holdings to the portfolio during the quarter: SK Hynix, Lonza and CATL. Each business provides substantial long-term opportunities in its respective fields: AI infrastructure, biologic drug manufacturing and battery technology. Lonza brings exposure to the long-term growth of complex medicines through a trusted manufacturing partner. As a biologics-focused contract development and manufacturing organisation (CDMO), Lonza helps customers develop and produce medicines that demand consistent execution at scale in a highly regulated environment. These capabilities are difficult to replicate and become more valuable as biologic drugs grow in importance. It gives us broad exposure to biotech innovation without the single-asset risk.” | NEUTRAL | Q2 2026 Jul 23, 2026 | View Pitch |
Mayar Capital Abdulaziz A. Alnaim | “Lonza Group AG is the premier contract manufacturer for complex biologic drugs, enjoying high customer retention due to deep integration with clients' regulatory filings and supply chains. The business is supported by strong structural tailwinds as pharmaceutical companies shift pipelines to biologics and outsource production. Having transitioned into a pure-play manufacturer, Lonza is projected to deliver low-double-digit growth and expanding margins, justifying its premium valuation.” | BULL | Q2 2026 Jul 3, 2026 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
